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Abstract
Cholangiocarcinomas (CCAs) are malignant tumors that can develop anywhere 
along the biliary tree. Almost 10% of cholangiocarcinomas arise from the intra-
hepatic bile ducts (iCCA); 50–60% from the bifurcation of the hepatic duct (perhi-
lar cholangiocarcinoma, pCCA); and 20–30% from the distal bile duct (dCCA). The 
7th edition of the AJCC staging system, released in 2010, divides the tumors into 
two major categories: perihilar (pCCA) and distal (dCCA) cholangiocarcinoma, 
given the differences in anatomy of the bile duct and consideration of local factors 
related to resectability. There are separate histological classifications for intrahe-
patic and extrahepatic cholangiocarcinoma. The majority of CCAs (90%) are well 
or moderately differentiated adenocarcinomas. Other features include invasiveness 
with early neural, perineural, periductal and lymphatic infiltration (more than 50% 
of cases at diagnosis) and longitudinal subepithelial infiltration along the wall of 
the bile duct up to 2 cm proximally and 1 cm distally. In this chapter the extrhepatic 
bile duct cancers are analyzed.
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1. Introduction
Cholangiocarcinomas (CCAs) are malignant tumors that can develop anywhere 
along the biliary tree [1]. Almost 10% of cholangiocarcinomas arise from the 
intrahepatic bile ducts (iCCA); 50–60% from the bifurcation of the hepatic duct 
(perihilar cholangiocarcinoma, pCCA), previously called Klatskin from the name 
of the author who first described it in 1965; and 20–30% from the distal bile duct 
(dCCA) [2]. In the previous editions of the American Joint Committee on Cancer 
(AJCC), staging system of extrahepatic bile duct tumors has been considered as a 
single entity [3]. The seventh edition of the AJCC staging system, released in 2010, 
divides the tumors into two major categories: perihilar cholangiocarcinoma (pCCA) 
and distal cholangiocarcinoma (dCCA) [4], given the differences in anatomy of the 
bile duct and consideration of local factors related to resectability [5]. For epide-
miological findings it is advisable to avoid misclassification and to define subtypes 
according to the WHO classification as iCCA, pCCA, and dCCA [6–8].
There are separate histological classifications for intrahepatic and extrahepatic 
cholangiocarcinoma. The majority of CCAs (90%) are well- or moderately dif-
ferentiated adenocarcinomas with a tendency to develop intense desmoplastic 
reactions due to the rapid proliferation of the tumor-associated stromal cells and 
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cancer-associated fibroblasts. Other features include invasiveness with early neural, 
perineural, periductal, and lymphatic infiltration (more than 50% of cases at 
diagnosis) and longitudinal subepithelial infiltration along the wall of the bile duct 
up to 2 cm proximally and 1 cm distally [9].
Although there is little data on this neoplasm, incidence rates and mortality 
seem to be declining in many countries. Through analysis of the SEER database, the 
mortality rate in the United States fell from 0.6 to 0.3 per 100,000 and incidence 
rates from 1.08 to 0.82 per 100,000. These data are probably more difficult to 
obtain because of the common ICD classification for both gallbladder and extrahe-
patic CCA tumors [10].
pCCA is the most common form with variable prevalence according to geo-
graphic areas, between 46 and 97% [4, 11, 12]. pCCA is diagnosed earlier and 
smaller than the intrahepatic variant because of its early presentation with indolent 
jaundice in 90% of cases or with cholangitis in about 10%. The infiltrative periduc-
tal histotype is the most common form; the exophytic mass-forming or intraductal 
papillary is less frequent [13]. Distal cholangiocarcinoma (dCCA) may derive from 
two precursors, recognized in the last WHO classification: intraductal papillary 
neoplasia and biliary intraepithelial neoplasia [14]. Similar to the pCCA, patients 
present at the onset of cholestatic jaundice and cholangitis secondary to biliary 
obstruction.
The prognosis is generally poor with a 5-year survival that is less than 5%. The 
median survival rate for patients with the intrahepatic variant is between 18 and 
30 months; however, the perihilar variant has a median between 14 and 24 months. 
The only curative therapeutic option can be expected from liver surgery for early-stage 
tumors. After surgery, the recurrence rate is between 60 and 90%. However, given 
that most patients come to the attention of the surgeon with an advanced stage of 
disease, thus precluding the surgical option, 75% of patients die 1 year after diagnosis. 
The main causes of death among patients are cachexia, liver failure, and sepsis due to 
biliary tract obstruction. Although 1-year survival increased from 16% (1975–1979) to 
28% (1995–1999), the 5-year survival showed no significant change [2].
2. Preoperative biliary drainage
2.1 Obstructive jaundice
Biliary obstruction leads to numerous pathophysiological consequences both at a 
local level, in the biliary tree, and at a systemic one. Affected patients are at high risk 
of liver insufficiency, renal failure, heart failure, coagulopathy, immunodeficiency, 
infectious complications, and, therefore, increased morbidity and mortality [15].
2.1.1 Local effects
Pressure inside the biliary tree is normally between 5 and 10 cmH2O, but in case 
of complete obstruction, it can reach 30 cmH2O. The biliary secretion is prevented 
when it exceeds the value of 10 cmH2O [16]. Cholestasis favors bacterial overgrowth 
of the bile which, under normal conditions, is sterile. Furthermore, biliary hyper-
tension causes a “cholangio-venous” reflux sustained by the increased permeability 
of bile ductules, thus favoring bacterial translocation and finally severe infections 
and sepsis [17, 18], as well as periportal neutrophilic infiltrate [19].
Increased pressure in the biliary system can gradually reduce the production 
of bile. However, the risk of lithogenesis is low due to the greater reduction in the 
secretion of cholesterol and phospholipids than bile salts (which guarantee the 
3Bile Duct Cancer: Preoperative Evaluation and Management
DOI: http://dx.doi.org/10.5772/intechopen.85840
solubility of cholesterol in the bile). When the obstruction is resolved, the restora-
tion of cholesterol and phospholipid secretion is inversely faster than the bile salt 
ones, thus favoring the lithogenesis responsible for the early obstruction of biliary 
stents [19, 20].
2.1.2 Systemic effects
Jaundice influences liver metabolic and synthetic function. The inhibition of 
cytochrome P450 and the reduction of aerobic and oxidative metabolism lead to 
an increase in oxidative stress, cell apoptosis, and alteration of drug metabolism. 
The reduced liver synthetic capacity leads to a reduction in the levels of albumin, 
coagulation factors, and immunoglobulins [20].
The proliferation of the intestinal microbial flora is favored by the interruption 
of the recirculation of the bile salts and is associated with the dysfunction of the 
intestinal mucosal barrier and the bacterial translocation with consequent increase 
in the absorption of endotoxins hereby produced [19]. Increased intestinal perme-
ability also plays a key role in the development of a potential septic state and renal 
complications [21].
Endotoxin (lipopolysaccharide) is usually inactivated by the hepatic reticulo-
endothelial system, but organ dysfunction—associated with increased endogenous 
production—leads to a systemic inflammatory response syndrome (SIRS) that may 
result in the multi-organ dysfunction syndrome (hemodynamic instability and 
renal failure) [22–25].
Acute renal failure occurs in 10% of jaundiced patients. This complication is 
associated with high mortality (70–80%). In addition, endotoxinemia stimulates 
the secretion of vasoactive prostaglandins and cytokines that are responsible 
for tubular necrosis and fibrin deposition with further reduction of glomerular 
 filtration [26–28].
The alteration of the immune system and the septic manifestations are mainly 
due to the insufficiency of the cellular immunity (T lymphocytes) induced by the 
release of cytokines (TNFα, IL-1, IL-6, IFNɣ), prostaglandins, and other mediators 
of inflammation [29–31].
The hemorrhagic diathesis is due to coagulation disorders induced by both 
complement activation and reduced hepatic prothrombin and other vitamin 
K-dependent factors (VII, IX, X, C-S-Z protein synthesis). The absence of bile salts 
in the intestine prevents the absorption of vitamin K [32].
2.2 Guidelines
2.2.1 Perihilar cholangiocarcinoma
In patients with perihilar cholangiocarcinoma and jaundice, the National 
Comprehensive Cancer Network (NCCN) guidelines recommend to consider 
preoperative biliary drainage. The decision should be always made by a multidis-
ciplinary team at an HPB center. The different expertise of the different centers 
significantly affects the choice between the endoscopic and the percutaneous 
approach. Bile drainage can be performed either endoscopically or percutaneously. 
There are currently no randomized clinical trials comparing these two types of 
drainage. Most retrospective studies have not shown any significant differences, 
both in terms of bilirubinemia reduction and complications [33]. The effectiveness 
of preoperative biliary drainage was analyzed by Farges et al. [34] in a multicenter 
retrospective study performed on 366 patients who underwent pCCA resection 
between 1997 and 2008 with right or left hepatectomy without resection of the 
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pancreatic head. One hundred and eighty patients (180/366; 49.1%) received 
biliary drain placement. Although drainage did not result in a significant change in 
postoperative mortality, a subanalysis showed a decrease in normalized postopera-
tive mortality for preoperative bilirubin in patients undergoing right hepatectomy 
(adjusted OR = 0.29; CI 0.11–0.77; p = 0.013) and an increase in postoperative mor-
tality in patients undergoing left hepatectomy (OR = 4.06 CI 1.01–16.3; p = 0.035). 
In particular, the cause of major postoperative mortality in the right hepatectomy 
group was liver failure and sepsis in the left hepatectomy group. Endoscopic 
nasobiliary drainage seems to be the most appropriate method of PBD in terms of 
minimizing the risks of tract seeding and inflammatory reactions [33].
2.2.2 Distal cholangiocarcinoma
The latest guidelines issued by the NCCN for the endoscopic treatment of biliary 
obstruction in dCCA recommend different treatments based on clinical status 
(Table 1) [35].
One of the reasons for greater debate concerns the balance between risks and 
benefits in the preoperative stenting of neoplastic biliary obstruction in resectable 
patients. The meta-analyses that investigated this topic concluded that preoperative 
biliary drainage should not be performed routinely, given the absence of difference 
in mortality but, above all, the increased associated morbidity [36–39]. However, 
stenting is recommended in patients with cholangitis, pruritus, coagulopathy, and 
renal failure or for whom surgical treatment is delayed for at least 1 week [35]. The 
scientific debate is also open regarding the type of stent, plastic or metal (partially 
or completely coated). It has been shown that coated metal stents have a lower 
dislocation rate and a longer patency time [40]. On the other hand, plastic stents 
are easier to position or replace and have an advantageous cost-benefit profile. 
However, a recent meta-analysis has shown that in patients with an overall survival 
of more than 6 months, the placement of the metal stent is associated with a better 
cost-benefit and quality of life [41]. Patency duration, morbidity, mortality, and 
repositioning rates were investigated in other studies [42–45] that demonstrated 
the superiority of the metal stent (short intrapancreatic or coated) due to increased 
patency resulting in a reduced need for additional endoscopy. The guidelines 
compiled by the NCCN and the European Society of Gastrointestinal Endoscopy 
(ESGE) indicate as a first choice the plastic stent in patients diagnosed with uncer-
tain malignancy and those with an unfavorable prognosis (≤3 months according to 
NCCN; ≤4 months according to ESGE) [35, 46].
Status Recommendation
Resectable tumor, jaundice Preoperative biliary drainage only in symptomatic patients 
(cholangitis, fever, pruritus, sepsis, coagulopathy, renal failure) or in 
which the surgical program is delayed by at least 1 week
Plastic or metal stent (if diagnosis histologically confirmed)
“Borderline resectable” tumor, 
candidate for neoadjuvant therapy, 
jaundice
Self-expanding metal stent
Unresectable tumor, 
intraoperative finding, jaundice
Self-expanding metal stent if no surgical bypass is performed during 
surgery
Metastatic tumor, jaundice Self-expanding metal stent*
*Many members of the NCCN panel point to the plastic stent in patients with a life expectancy of less than 3 months.
Table 1. 
Neoplastic biliary obstruction. NCCN endoscopic treatment guidelines.
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3. Liver function tests
pCCA surgical approach may also require extended liver resection. The hepatic 
parenchyma must be removed, but also the residual volume and its ability to 
guarantee acceptable residual liver function must be carefully assessed [47]. In 
2011 the International Study Group of Liver Surgery published and updated the 
posthepatectomy liver failure definition and grading [48]. Posthepatectomy liver 
failure (PHLF) has been defined as an “acquired deterioration in the ability of the 
liver to maintain its synthetic, excretory and detoxifying functions, characterized 
by an increased INR, and hyperbilirubinemia on or after postoperative day 5.” PHLF 
is then differentiated into three grades (A, B, and C) based on clinical and invasive 
management [48]. The presence of liver disease and liver function correlates with 
the critical residual liver volume able to predict PHLF. The limit for a safe resection 
ranges from 20 to 30% future remnant liver among patients with normal liver func-
tion. However, this limit must be raised to over 40% in case of risk factors related to 
patient, liver, or surgery [47].
3.1 Volumetry
Computed tomography and magnetic resonance imaging are used increasingly 
to measure liver volume in patients evaluated for resection. Numerous factors 
can influence the accuracy of preoperative liver volumetry: the phase of contrast 
administration, slice thickness, use of CT versus MRI, varying image processing 
software, and inter-user variability, as well as the degree to which non-parenchymal 
structures are erroneously included within the functional liver volume [49].
In 2002 Vauthey published the formula to estimate total liver volume (TLV) 
based on body surface area (BSA). The formula obtained was TLV = 794.41 + 
1267.28 × BSA (m2), and a formula based on patient weight also was derived: 
TLV = 191.80 + 18.51 × weight (kg) [50].
In 2015 Martel compared the two techniques, the measured and the estimated 
liver volume, to determine the accuracy and variability of each volumetric method 
[49]. The conclusion of his study is that TLV is best evaluated by direct radiologic 
measurement rather than by indirect estimation. Indeed, estimated volumetry 
leads to a clinically significant over- or underestimation of the future liver remnant 
(≥5% in 31.9% of patients) and is more frequently associated with an underes-
timation of the estimated TLV and an overestimation of the estimated remnant 
future liver ratio [49].
3.2 Indocyanine green clearance test
Many quantitative liver function tests have been proposed, but they are imprac-
tical in a clinical setting because of excessive cost, need for multiple samples and 
prolonged catheterization, and risk of allergic reaction. Indocyanine green (ICG) 
clearance test is considered the most predictive test of operative mortality after 
hepatectomy if compared to other tests such as the amino acid clearance test or 
aminopyrine breath test [51]. The indocyanine green dye is absorbed by the hepa-
tocytes and excreted via the biliary tract without enterohepatic recirculation. The 
percentage of retention can be measured by pulsed spectrophotometry using an 
optical sensor [52]. The ICGR15 describes the percentage of circulatory retention 
of indocyanine green during the first 15 min after bolus injection. The cutoff value 
of ICG retention normal value in healthy patients is between 8 and 15%, and the 
cutoff value that allows a major hepatectomy is between 14 and 17% [53, 54]. Minor 
resections may be performed for values that reach 22% and limited hepatectomies 
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(bisegmentectomies) to values up to 40%. Some authors claim that laparoscopic 
limited wedge resections could be tolerated for values even greater [55]. Bilirubin 
and indocyanine green bind to the same carrier in the transport phase in hepato-
cytes, determining a competitive inhibition. For that reason, ICG retention is not 
valid in jaundiced patients.
4. Portal vein embolization
Portal vein embolization (PVE) is indicated in patients in whom a major resection 
or a parenchymal resection of more than 50–60% of the TLV is programmed, with 
the goal to prevent or reduce the risk of posthepatectomy liver failure [Benson 2014]. 
Although there are no randomized trials comparing the operative risk in patients sub-
jected or not to PVE, a reduction in mortality is demonstrated from the retrospective 
series present in the literature in up to 0–2% of patients resected after PVE [Benson 
2014]. In contrast, mortality rates vary between 10 and 21% in HPB centers where the 
indication to the PVE has been given with a residual liver volume less than 25–30%.
5. Preoperative staging systems
5.1 Perihilar cholangiocarcinoma
The Bismuth-Corlette classification is the most used to program the best derivative 
approach because it evaluates the longitudinal tumor extension. Four types of pCCA 
are distinguished based on their perihilar extension: type I, tumor confined to the 
common hepatic duct; type II, tumor limited to the confluence of the hepatic duct, 
without involvement of the second-order ducts; type III, tumor involving the conflu-
ence with extension to the right (IIIA) or left (IIIB) hepatic duct; and type IV, tumor 
affecting the biliary confluence with the involvement of secondary intrahepatic ducts 
on both sides. This system is used to plan the surgical treatment, from the resection 
(type I and II) to a major hepatectomy (type III). Type IV is traditionally considered 
nonsurgical, except for liver transplantation [56], but recently, curative surgery has 
also been attempted in type IV tumors that extend backward for less than 2 cm from 
the hilum. However, the Bismuth-Corlette classification system lacks important 
resectability information such as vascular infiltration, local or distant lymph node 
metastatic spread, and lobar hepatic atrophy, and therefore this system has no prog-
nostic value and does not correlate with survival results [57, 58]. Moreover, in some 
cases, a precise Bismuth-Corlette classification can be difficult to define at the imaging 
due to the poor definition of the longitudinal extension in case of subepithelial infil-
tration (infiltrative forms) or of mucosal diffusion (papillary polypoid forms) [13].
The classification proposed by the Memorial Sloan-Kettering Cancer Center 
(MSKCC) details three factors related to tumor extension: the position and extent 
of biliary involvement (similar to the Bismuth-Corlette classification), portal 
vein invasion, and hepatic lobar atrophy, independently of lymph node or distant 
metastases. It is used for the selection of patients fit for surgery [59].
In the seventh edition of the AJCC/UICC staging system, the pCCA was staged 
as a separate entity based on anatomo-pathological staging (pathological TNM). 
The AJCC system also considers involvement of the portal vein and hepatic artery, 
lymph node status, and distant metastases. It is mainly used as a postoperative 
staging system and has a minimal utility to assess the resectability. An initial stage 
tumor (T1) is limited to the bile duct wall. T2 tumors extend beyond the bile 
duct wall, invading the periductal fat (T2a) or liver (T2b), and often present as 
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periductal infiltrative forms or as a nodular mass showing irregular duct wall thick-
ening with contrast enhancement. The T3 stage includes locally invasive lesions 
involving the liver, gallbladder, pancreas, or ipsilateral portal vein or hepatic artery. 
The T4 stage includes widely invasive tumors, with bilateral extension to the portal 
vein or to the main portal trunk, the common hepatic artery, the contralateral vas-
cular extension, and the involvement of the second-order bile ducts or to adjacent 
organs (colon, stomach, duodenum, or abdominal wall). The involvement of the 
hepatic parenchyma is classified as T2 instead of T3 since parenchymal involvement 
alone has a better prognosis than unilateral vascular involvement.
Numerous experiences have shown inaccuracies offered by the AJCC system, 
which may, in part, be due to not having taken into account the depth of the tumor 
invasion [60]. Given the limitations of the various staging systems and the difficulty 
in comparing the results in various centers, DeOliveira and an international panel of 
experts have introduced a new staging system for the pCCA, which also includes new 
factors to improve and standardize the determination of prognosis and tumor report-
ing [61]. This new system is derived from the Bismuth-Corlette classification for the 
evaluation of the involvement of the biliary tree but also considers (a) the size of the 
tumor (diameter >1 cm, 1–3 cm, or ≥3 cm); (b) tumor morphology, periductal or 
nodular-sclerosing or mass-forming, intraductal or polypoid, and mixed; (c) degree 
and position of the hepatic artery infiltration and of the portal vein encasement; 
(d) hepatic lobar atrophy and future liver remnant volume; (e) other liver diseases 
(fibrosis, nonalcoholic steatohepatitis, or PSC); (f) lymph nodes; and (g) distant 
metastases, including the liver and peritoneal ones. Therefore, this staging is appli-
cable in the preoperative setting and includes well-established prognostic factors. The 
inclusion of the type of macroscopic tumor growth has never been included in other 
staging systems and has been shown to be a predictor of survival [62]. However, this 
staging system is rather complicated and also includes some prognostic factors not 
yet validated, such as tumor size, lobar atrophy, and the volumetric analysis [59]. The 
validity of this new system still needs verification in large prospective studies.
5.2 Distal cholangiocarcinoma
The first classification system that has assigned a definition for the dCCA 
separated from the pCCA is the seventh edition of the AJCC/UICC classification. 
This has been an important step because the differences between the two extrahe-
patic forms have been recognized. For example, the depth of ductal invasion and 
pancreatic invasion is significantly more common in dCCA [63]. Indeed, depth of 
invasion, lymph node metastasis, perineural and microscopic vascular invasion as 
well as the invasion of the pancreas, and the R0 resection are significant survival 
predictors [64, 65]. The pattern of lymph node metastasis differs between the three 
types of CCA and is most commonly observed in the dCCA [66]. Several studies 
have suggested that the number of pathological lymph nodes is an independent 
prognostic factor; more than two metastatic lymph nodes are predictive of a worse 
prognosis. In the AJCC classification, the T stage distinguishes T1 and T2 tumors 
based on the microscopic tumor growth pattern if confined to the bile duct or 
beyond it. The TNM staging system shares some of the features of the pCCA: 
T1 and T2 tumors are confined to the bile duct wall (T1) or invade the bile duct 
without invasion to adjacent organs (T2). Invasion of adjacent organs (pancreas, 
stomach, and duodenum) is considered T3. The invasion of the celiac tripod and 
superior mesenteric artery is considered T4. Moreover, the TNM classification 
presents similarities with that of pancreatic cancer. The lymph node staging has two 
stages (N0 and N1). Unlike proximal tumors, lymph node staging is performed at 
the time of surgery with the sampling of at least 12 lymph nodes.
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